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Abstract Neuroinflammation is typically observed in
neurodegenerative diseases such as Alzheimer’s disease, as
well as after traumatic injury and pathogen infection. Resi-
dent immune cells, microglia and astrocytes, are activated
and joined by blood-borne monocytes that traverse the
blood–brain barrier and convert into activated macrophages.
The activated cells express various cytokines, chemokines
and proteolytic enzymes. To study the role of heparan sul-
fate proteoglycans in neuroinflammation, we employed a
transgenic mouse overexpressing heparanase, an endoglu-
curonidase that specifically degrades heparan sulfate side
chains. Neuroinflammation was induced by systemic chal-
lenge with lipopolysaccharide, or by localized cerebral
microinjection of aggregated amyloid-b peptide, implicated
in Alzheimer’s disease. Lipopolysaccharide-treated control
mice showed massive activation of resident microglia as
well as recruitment of monocyte-derived macrophages into
the brain parenchyma. Microinjection of aggregated amy-
loid-b elicited a similar inflammatory response, albeit
restricted to the injection site, which led to dispersion and
clearance of the amyloid. In the heparanase-overexpressing
mice, all aspects of immune cell recruitment and activation
were significantly attenuated in both inflammation models,
as was amyloid dispersion. Accordingly, an in vitro blood–
brain barrier model constructed from heparanase-over-
expressing cerebral vascular cells showed impaired
transmigration of monocytes compared to a corresponding
assembly of control cells. Our data indicate that intact
heparan sulfate chains are required at multiple sites to
mediate neuroinflammatory responses, and further point to
heparanase as a modulator of this process, with potential
implications for Alzheimer’s disease.
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Introduction
Neuroinflammation is a prominent feature of several path-
ological conditions of the central nervous system (CNS),
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including neurodegenerative diseases such as Alzheimer’s
disease (AD) [1, 25], CNS autoimmune diseases [5], trau-
matic brain injury [63] and pathogen infection [7]. Resident
immune cells (microglia and astrocytes) are activated to
release various cytokines, chemokines and proteolytic
enzymes [38, 58]. Moreover, the cerebral parenchyma is
invaded by blood-borne monocytes that traverse the blood–
brain barrier (BBB) and convert into activated macrophages
[16, 45]. The mechanisms behind these events are only partly
understood, and the pathophysiological consequences of
neuroinflammation are diverse and complex.
In AD, aggregated 40- or 42-residue peptides of amy-
loid-b (Ab) deposit in the brain parenchyma as
extracellular senile plaques and typically throughout the
vasculature as cerebral amyloid angiopathy.
Seemingly contradictory effects of neuroinflammation
have been noted in AD, on the one hand deposits appear to
induce inflammatory reactions that recruit immune cells
capable of dispersing the plaques, contributing to their clear-
ance from the tissue [3, 52]. The relevance of these
phenomena to the disease course is unclear, particularly so
since soluble intermediate Ab aggregates rather than fibrils
have been directly implicated with neurotoxicity [20, 32].
Nevertheless, reactions leading to dispersal of Ab deposits are
potentially beneficial and merit characterization. Efficient Ab
phagocytes are believed to be derived from blood-borne
monocytes that are recruited into the brain, where they dif-
ferentiate to macrophages in the course of a complex
neuroinflammatory response [9, 16]. The mechanism of cell
recruitment across the blood–brain barrier (BBB) is only
partly understood.
Previous studies demonstrated a key role for cell-surface
heparan sulfate (HS) proteoglycans (HSPGs) in regulating
leukocyte transmigration from blood to sites of inflammation
[27, 33, 60]. The present study was undertaken to clarify the
involvement of HS in neuroinflammation, induced either by
systemic challenge with bacterial lipopolysaccharide (LPS)
or by local deposition of Ab fibrils in murine brain. We
employed a transgenic mouse overexpressing heparanase
(Hpa-tg), an endoglucuronidase that specifically degrades
HS [11]. The Hpa-tg mice showed attenuated inflammatory
response compared to control (Ctr) mice, and an impaired
ability to disperse and clear Ab aggregates. Moreover, HS
and heparanase were directly implicated with regulation of
monocyte transmigration across the BBB.
Materials and methods
Mice
The transgenic mouse overexpressing human heparanase
(Hpa-tg), under the b-actin promoter, were generated
according to Zcharia et al. [62], except that the enzyme was
expressed as a chimer containing a chick heparanase signal
peptide sequence, which promotes enzyme secretion [18].
The transgenic mice were backcrossed more than 10 gen-
erations on a C57BL/6 background and C57BL/6 was used
as control (Ctr). The mice were used at 3–20 months of
age. All experiments were approved by the regional animal
research ethics committee.
Determination of heparanase expression level
Heparanase ELISA was performed as described by Shafat
et al. [50].
Isolation and analysis of HSPG
Isolation and analysis of HSPG were performed as previously
described [11]. See Supplementary methods for details.
Lipopolysaccharide (LPS) treatment
Mice (4-month-old) were intraperitoneally injected with a
single dose (5 mg/kg) of LPS (10 lg/100 ll PBS) (LPS
L2280, derived from O55:B5 E.coli, Sigma-Aldrich). After
20 h the mice were deeply anesthetized, transcardially per-
fused with 50 ml saline, and the brains were dissected. One
hemisphere of the brain was fixed in 4 % formaldehyde for
cryotome tissue section preparation and the other was rapidly
frozen in dry ice for preparation of tissue extract.
Western blotting
Protein samples were separated by 10–20 % SDS-PAGE
and then transferred to a nitrocellulose membrane. After
blocking with 5 % nonfat dry milk, the membranes were
probed with primary antibodies (see Supplementary
Table 1 for an account of all antibodies used in the study)
followed by the corresponding secondary antibodies. Sig-
nals were visualized using SuperSignal West Pico or Dura
substrates (Thermo). Quantitative band analysis was per-
formed with ImageJ software.
Intracortical Ab42 injection
The injection was performed on deeply anesthetized (2.5 %
avertin 500 ll/mouse i.p.) mice under stereotaxic guidance
with coordinates from the bregma: ?2.0 mm anteroposte-
rior, -2.0 mm lateral, and -2.3 mm dorsoventral. Five
micrograms of aggregated synthetic human Ab1-42
(PolyPeptide Laboratories GmbH, Germany) (5 lg/1 ll)
was injected into one hemisphere at a rate of 0.2 ll/min,
followed by a 2-min pause for absorption of the injected
solutions. The brains were dissected as described above,
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fixed in 4 % formaldehyde overnight and processed
according to standard protocols for the preparation of
paraffin-embedded tissue blocks.
Histochemistry and immunostaining
Immunostaining with antibodies against CD45, F4/80,
CD31 and ICAM-1 were performed on 20 lm cryotome
brain tissue sections. All other immunostainings and Congo
red histochemistry were performed on 5 lm paraffin sec-
tions. After antigen retrieval, primary antibody incubation
was carried out overnight at 4 C followed by incubation
with secondary antibody for 30–60 min at room tempera-
ture. ABCTM complex and NOVATM red reagents (Vector
Labs) were used to visualize the immunosignals. In another
setting, a rat on mouse AP-polymer kit, developed with
Vulcan Fast Red Chromogen kit2 (Biocare Medical) was
employed. For double immunostaining, primary antibodies
were incubated overnight, simultaneously or stepwise at
4 C, followed by incubation with the appropriate Alexa
fluor labeled secondary antibodies (Invitrogen). Hematox-
ylin and DAPI (40,6-diamidino-2-phenylindole) were used
for counterstaining of nuclei.
Microscopy and image analysis
Microscopy was performed using a Nikon DXM1200FTM
instrument (Nikon, Melville, USA). CD45-positive cells
associated with microvessel walls or partially exited from
vessels were counted under microscope and the number of
such cells associated with 10 microvessels of similar
length (*300 lm) in each section was summarized.
Images of anti-F4/80 and anti-CD45 immunostained sec-
tions were captured and the positive cells were quantified
with ImageJ software. The images were converted to 8-bit
grayscale format and a standard segmentation threshold for
positively stained pixels was established. Using the ImageJ
particle analysis tool with a size setting of 8–20 pixels, the
number of amoeboid and ramified CD45-positive cells was
recorded and with a setting of 20–100 pixels, the number
of F4/80-positive cells was recorded. Cross-sectional
information and z-stacks for selected deposits were
obtained by confocal laser scanning microscopy using a
Carl Zeiss LSM 510 METATM instrument (Carls Zeiss,
Germany).
In vitro BBB model and monocyte transmigration
Primary endothelial cells and pericytes were prepared from
the brains of Hpa-tg and Ctr mice. The in vitro BBB model
was constructed on FalconTM HTS FluoroBlokTM 3.0 lm
colored PET Membrane Inserts for 24 well culture plates
(BD). Pericytes (10,000 cells/insert) were grown on the
basolateral side and endothelial cells (150,000 cells/insert)
on the apical side of the membrane, which was pre-coated
with bovine fibronectin. The cells were grown for 3 days
prior to experiments. The integrity of the endothelial
monolayer was confirmed by establishing that Evans blue-
bound BSA did not diffuse from the apical to the baso-
lateral compartment. GFP-monocytes (120,000 cells/insert)
were, immediately after isolation, loaded into the apical
compartment (blood), and 50 ng/ml of CCL2 was added to
the basolateral compartment (brain). Monocytes migration
from the apical to the basolateral compartment was mon-
itored with a Zeiss laser scanning microscope LSM
700/CO2 Microscope with a stage incubator (37 C, 5 %
CO2). The number of GFP-monocytes was counted with
ImageJ software. For details, see Supplementary methods.
Statistical method
Two-tailed unpaired Student’s t test was used to determine
the significance between population means. Statistical
significance was set at P \ 0.05.
Results
Cerebral expression of heparanase and altered HS
structure in transgenic mice
We have previously described a transgenic mouse over-
expressing human heparanase, which results in extensive
fragmentation of HS chains in vivo [11, 62]. To study the
role of HS in neuroinflammation, we generated a new strain
(Hpa-tg) that overexpresses a high level of heparanase in
the brain. The transgenic enzyme was expressed, albeit to
variable extent, in all examined regions of the brain
(Fig. 1a, b). Gel chromatography of metabolically radio-
labeled HSPG isolated from Hpa-tg brain detected HS
fragments that were not present in Ctr brain tissue
(Fig. 1c). Disaccharide compositional analysis revealed a
decrease in the -GlcA-GlcNS6S- unit, representing the
cleavable linkage target for heparanase (Fig. 1d; peak 2),
and an increase in trisulfated -IdoA2S-GlcNS6S- disac-
charide (Fig. 1d; peak 5), as previously ascribed to
heparanase upregulation [11].
Reduced cerebral inflammatory response to LPS
challenge in Hpa-tg mice
LPS is a bacterial endotoxin known to upregulate cerebral
expression of pro-inflammatory factors such as interleukin-
1b (IL-1b) [22], tumor necrosis factor a (TNF-a) [44] and
CCL2 (also designated monocyte chemotactic protein-1)
[55]. Once released, the pro-inflammatory factors stimulate
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recruitment of neutrophils [47], and activation of microglia
[44]. We examined the cellular response of the Hpa-tg brain
to LPS treatment. Brain tissue sections of 4-month-old, LPS-
challenged mice were immunostained with antibodies
against CD45, a major protein tyrosine phosphatase located
at the leukocyte plasma membrane [56] and F4/80, a gly-
coprotein cell-surface marker that is amply expressed by
murine macrophages [2]. Anti-CD45 antibody strongly
stained cells with amoeboid morphology in association with
microvasculature (Fig. 2a, e–f) and in the parenchyma
(Fig. 2j; left insert). This phenotype is primarily associated
with macrophages derived from blood-borne monocytes
[19], which was supported by the detection of CD45-positive
cells at various stages of transmigration (Fig. 2b; i–iv),
including cells attached to the luminal wall (Fig. 2c). The
transmigration process is outlined in the graphic in Fig. 2d.
To assess transmigration of blood-borne monocytes, we
counted the CD45-positive cells associated with microvas-
culature (Fig. 2e, f) and found significantly more CD45-
positive cells in Ctr than in Hpa-tg mice (Fig. 2g). Resident
microglia are characterized by highly branched morphology
and low levels of CD45 [41, 49] that are upregulated in the
course of activation [14, 42]. We counted CD45-positive
cells of ramified and amoeboid morphology (Fig. 2h–j;
inserts) in whole tissue sections and found, again, signifi-
cantly increased numbers of CD45-positive cells in Ctr
compared to Hpa-tg mice (Fig. 2j). Immunostaining with
anti-F4/80 antibody revealed a massive recruitment of acti-
vated macrophages in Ctr brains (Supplementary Fig. 1a:
insert, b). Again, such cells were less abundant in Hpa-tg
brains (Supplementary Fig. 1c). The abundant ramified
macrophages presumably include activated resident
microglia as well as cells derived from blood-borne mono-
cytes. Mice of similar age, not challenged with LPS showed
few CD45- and F4/80-positive cells, irrespective of Ctr or
Hpa-tg status (Supplementary Fig. 1d-g). Consistent with
these findings, protein levels of the pro-inflammatory cyto-
kine IL-1b were significantly higher in LPS-challenged Ctr
brains than in Hpa-tg brains (Fig. 2k). Heparanase overex-
pression thus attenuates recruitment of inflammatory cells
into the brain and reduces activation of resident microglia in
response to systemic LPS challenge.
Delayed clearance of injected Ab42 and poor
recruitment of immune cells in Hpa-tg brain
We also assessed the impact of heparanase overexpression
on locally induced neuroinflammation elicited by
Fig. 1 Changed structure of heparan sulfate in mouse brain due to
heparanase overexpression. a Paraffin-embedded sagittal brain sec-
tions of Hpa-tg (left) and Ctr (right) mice were immunostained with
anti-heparanase antibody 733 (red). b Heparanase levels in extracts of
Hpa-tg and Ctr brain tissue, analyzed with ELISA. Cere cerebellum,
Cort cortex, Hipp hippocampus, Stri striatum, Mid midbrain. c Gel
chromatography (Superose 6) of metabolically 35S-labeled HSPG
purified from Hpa-tg and Ctr brains. The elution position of heparin
(14 kDa) is indicated by the arrow. d Anion-exchange HPLC
(Partisil-10 SAX column) of disaccharides generated by deaminative
cleavage of HS derived from brain tissue extracts of Hpa-tg and Ctr
mice. The resulting disaccharides were radio-endlabeled by reduction
with NaB3H4. Numbered peaks represent the following disaccharide
units in the intact HS chains: 1 -GlcA2S-GlcNS-, 2 -GlcA-GlcNS6S-,
3 -IdoA-GlcNS6S-, 4 -IdoA2S-GlcNS-, 5 -IdoA2S-GlcNS6S-. The
proportions of peaks 2 (the disaccharide cleaved by heparanase) and 5
(Di-triS: hypersulfated disaccharide) are indicated as percentage of
total disaccharides
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intracortical injection of aggregated synthetic human Ab42
(Fig. 3a). Groups of 6–7 Ctr and Hpa-tg mice were killed
after 1, 2, and 4 weeks post-injection and brain sections
were immunostained using the anti-Ab antibody 6E10. The
newly injected material appeared as compact, 6E10
(Fig. 3b) and Congo red (not shown) positive deposits that
were dispersed (Fig. 3c) and ultimately cleared (Fig. 3d)
over time. Clearance was markedly delayed in Hpa-tg
compared to Ctr mice. Compact residual aggregates thus
remained at the injection sites in 10 out of 20 Hpa-tg mice
at time points when none were found in any of 18 Ctr mice
(Fig. 3e).
Fig. 2 Impaired immune response of Hpa-tg brain to LPS challenge.
Four-month-old Hpa-tg and Ctr mice received LPS (5 mg/kg) by
intraperitoneal injection, and were killed 20 h later and brain tissue
sections were immunostained with anti-CD45 antibody. a–d CD45-
positive cells associated with microvascular structures in Ctr brain:
a the morphologies of CD45-positive cells associated with the
vasculature are consistent with those assumed by monocytes transmi-
grating from the blood to the brain parenchyma, converting to
macrophages in the course of this process. b CD45-positive cells in
(i) and (ii) remain intravascular but are associated with the vessel wall,
whereas the cells in (iii) and (iv) have largely exited the vessel.
c Confocal laser scanning microscopy of the CD45-positive cell in (ii)
imaged with differential interference contrast (DIC). d Model of
monocyte attachment and diapedesis from blood to brain, typically
stimulated in response to CNS-derived chemokines. e–f CD45-
positive cells (indicated by arrows) associated with Ctr and Hpa-tg
microvasculature, respectively. g Significantly fewer CD45-positive
cells are associated with Hpa-tg than with Ctr microvasculature. The
data are presented, for each animal, as total number of CD45-positive
cells from 10 microvasculatures, each of *300 lm length. h, i Panels
to the right show high-magnification images of the cortical areas
indicated by frames in the left panels. j Top representative amoeboid
(left) and ramified (right) CD45-positive macrophages from either Ctr
or Hpa-tg sections; bottom Significantly fewer CD45-positive macro-
phages in Hpa-tg whole-brain tissue sections than in Ctr sections.
k Western blotting of IL-1b in Hpa-tg and Ctr brain. Densitometry
analysis of the bands demonstrated a significantly higher up-regulation
of IL-1b in Ctr brains than in Hpa-tg brains following LPS challenge
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To elucidate the reason for the impaired elimination of
Ab aggregates in the Hpa-tg brain, we examined injection
sites for reactive cells using anti-CD45 antibody for
detection of activated macrophages and anti-GFAP anti-
body for astrocytes. The dispersed Ab deposits, found in
Ctr mice, were heavily infiltrated by CD45-positive mac-
rophages (Fig. 4a), and surrounded by GFAP-positive
astrocytes (Fig. 4b), in contrast to the compact deposits in
Hpa-tg mice that showed only scant recruitment of cells
(Fig. 4c, d). Notably, dispersed deposits were also sur-
rounded by fewer reactive cells in Hpa-tg than in Ctr mice
(Supplementary Fig. 2). CD45-positive cells with amoe-
boid morphology were observed (4e-g), indicative of
monocyte origin, similar to those detected after the
LPS-induced inflammatory response. Confocal z-scan
demonstrated internalization of the injected Ab42 by CD45-
positive macrophages, confirming their phagocytic pheno-
type (Fig. 4h). These data associate delayed degradation of
the injected Ab with an impaired inflammatory response.
Degradation of Ab has been ascribed to proteases
expressed by neurons, glial cells, macrophages and cere-
bral vasculature, in particular neprilysin (NEP) and matrix
metalloproteinase-9 (MMP-9) [34]. To assess the impact of
these enzymes on the degradation of injected Ab, we
examined the expression of NEP and MMP-9 in brain
sections of a Ctr mouse that showed some remaining,
dispersed Ab (6E10-positive material, indicated by arrows
in Fig. 5a; insert) and a Hpa-tg mouse retaining compact
Ab deposits (Fig. 5d). Immunosignals of NEP and MMP-9
were restricted to the injection sites, confined to smaller
areas in Hpa-tg (Fig. 5e, f) than in Ctr brain (Fig. 5b, c).
Double immunostaining of Ctr and Hpa-tg sections
revealed expression of NEP mainly in CD45-positive
macrophages, whereas MMP-9 appeared primarily associ-
ated with astrocytes (Supplementary Fig. 3). In accordance
with these data, Ctr brain showed significantly higher NEP
and MMP-9 protein levels than Hpa-tg brain, following
systemic LPS challenge (Supplementary Fig. 1h, i). The
lower expression of these enzymes in the Hpa-tg mouse
brain thus correlates with a relative lack of activated
macrophages and astrocytes. These data confirm that the
delayed Ab clearance in the heparanase-overexpressing
brain is caused by impaired recruitment of inflammatory
cells that degrade Ab aggregates.
Reduced expression of CCL2 and ICAM-1
in Hpa-tg brain
The above results demonstrated impaired infiltration and
activation of immune cells in the Hpa-tg brain. Extrava-
sation of leukocytes from blood to affected tissues in
inflammation depends on leukocyte/endothelial cell rec-
ognition, which involves soluble chemotactic factors as
well as receptors and ligands on cell surfaces [4]. Expres-
sion of the chemotactic protein CCL2 was examined in
brain sections of a Ctr mouse with some residual, dispersed
Ab (Fig. 6a; insert) and a Hpa-tg mouse retaining compact
Ab deposits (Fig. 6b; insert). CCL2 immunosignals were
restricted to the injection site and were much more pro-
nounced in Ctr than in Hpa-tg brain (Fig. 6a, b). CCL2
appeared predominantly associated with CD45-positive
macrophages in both Ctr and Hpa-tg animals (Supple-
mentary Fig. 4).
The transmembrane protein ICAM-1 (intercellular
adhesion molecule 1, also known as CD54) is constitu-
tively expressed at low levels on the cell surface of various
Fig. 3 Ab deposits following intracortical injection of aggregated
synthetic human Ab42 in Ctr and Hpa-tg mice. a Ab42 injection site.
b Representative compact deposit at the injection site from a Hpa-tg
mouse. c Dispersed deposit, with scattered 6E10-positive aggregates.
d Cleared deposit. e Number of Hpa-tg and Ctr brains presenting with
each deposit state in groups killed after 1, 2, and 4 weeks
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cells types including endothelial cells and neutrophils, but
dramatically upregulated in response to cytokines and LPS
[8, 29, 30, 36, 47, 61]. We assessed ICAM-1 expression in
brain tissue sections of LPS-challenged mice by immuno-
staining with anti-ICAM-1 antibody. Ctr brain, with
upregulated IL-1b generation (Fig. 2k), showed ICAM-1-
Fig. 4 Cellular response to Ab injection. Adjacent brain sections
from mice, 2 weeks after Ab42 injection were double immunostained
with anti-Ab42 for Ab42 and anti-CD45 for macrophages or anti-
GFAP for astrocytes. a, b Ctr mouse. Anti-Ab42 stained dispersed Ab
deposits (a, b red), which were heavily infiltrated by CD45-positive
macrophages (a, green), and surrounded by GFAP-positive astrocytes
(b green). c, d Hpa-tg mouse. Anti-Ab42 stained compact Ab
deposits (c, d red) with scant recruitment of CD45-positive macro-
phages (c green) and GFAP-positive astrocytes (d green). Confocal
laser scanning microscopy of Ab42 (e, red) and CD45 (f, green)
immunostaining detects cells with amoeboid morphology (g, arrow)
and few short processes (g, arrowhead). Ab was engulfed by several
CD45-positive cells. h Confocal microscopy of phagocytosed Ab in a
CD45-positive phagocyte indentified by the frame in g
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positive cells in the parenchyma (Fig. 7a). By contrast,
Hpa-tg brain, with attenuated IL-1b response to LPS
(Fig. 2k), was essentially devoid of ICAM-1-positive cells
in the parenchyma (Fig. 7b). Double immunostaining with
anti-CD31 antibody for blood vessel and ICAM-1 antibody
showed ICAM-positive cells associated with microvascu-
lature in Ctr parenchyma (Fig. 7g–h, k–l), but few such
cells were found associated with Hpa-tg microvasculature
(Fig. 7i–j, m–n). Double immunostaining with anti-CD45
and anti-ICAM-1 antibodies revealed that the ICAM-1-
positive cells in the parenchyma (Fig. 7c–f) and the ICAM-
1 positive cells associated with blood vessel walls
(Fig. 7o–r) were also CD45-positive; hence the parenchy-
mal cells are likely derived from blood-borne monocytes.
These data are consistent with the view that ICAM-1
expression remains low until monocytes are in the process
of leaving the circulation [37]. We did not detect clear
upregulation of ICAM-1 on endothelial cells. It has been
reported that ICAM-1 expression on monocytes mediates
trans-endothelial migration [54]; thus the inhibited
expression of ICAM-1 may be attributed to the impaired
recruitment of CD45-positive macrophages in Hpa-tg
mouse. CD45-associated ICAM-1 expression was also
observed in brain sections of mice that had received in-
tracortical Ab42 injection (Supplementary Fig. 5) with
more pronounced ICAM-1 immunosignals around the
injection site in Ctr mice (Fig. 6c) than in Hpa-tg mice
(Fig. 6d).
Impaired transmigration of blood-borne monocytes
across an in vitro model of the Hpa-tg blood–brain
barrier
Endothelial HS is essential for leukocyte trafficking, as
demonstrated by impaired neutrophil infiltration in various
inflammation models due to deficient HS sulfation [60].
We therefore examined whether the scant recruitment of
CD45-positive cells into the brain of Ab-injected Hpa-tg
mice could be caused by derangement of HS chains on
cerebral microvascular endothelial cells. To this end, we
prepared primary cerebral endothelial cells and pericytes
from Hpa-tg and Ctr mice (Supplementary Fig. 6a-c) and
assembled an in vitro BBB model to study monocyte
transmigration (Fig. 8a). Both endothelial cells and peri-
cytes from Hpa-tg mice showed distinct overexpression of
heparanase (Fig. 8b–e). Similar to the HS isolated from
whole brain (Fig. 1c), the Hpa-tg endothelial HS was
truncated compared to Ctr HS chains (Fig. 8f). Monocytes,
isolated from Ctr mice expressing green fluorescent protein
(GFP) were added to the apical compartment of the
transmigration device, and their migration across the cel-
lular barrier was determined in response to CCL2 added to
the basolateral compartment (Fig. 8a). The number of GFP
monocytes settling in the basolateral chamber was signifi-
cantly reduced in the Hpa-tg compared to the Ctr BBB
model (Fig. 8g; Supplementary Fig. 7). Control experi-
ments performed without addition of CCL2 showed
Fig. 5 Expression of proteolytic enzymes following intracortical
Ab42 injection. Adjacent brain sections from a Ctr mouse and a Hpa-
tg mouse 4 weeks after intracortical injection of Ab42 were
immunostained with the anti-Ab antibody 6E10 (red in a, indicated
by arrows in insert, and red in d), anti-NEP antibody (b, e) and anti-
MMP-9 antibody (c, f), respectively. Immunosignals of NEP and
MMP-9 were restricted to the injection sites, confined to smaller areas
in Hpa-tg (e, f) than in Ctr brain (b, c)
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minimal numbers of monocytes crossing the insert (data
not shown), proving the active role of the chemoattractant
in the transmigration event. These data demonstrate that
perturbation of endothelial HS by heparanase significantly
impedes transmigration of blood-borne monocytes across
the BBB.
Discussion
Proliferation and recruitment of activated immune cells in
the brain parenchyma, including macrophages derived
from microglia or from blood-borne monocytes, is a hall-
mark of neuroinflammation. The inflammatory state may
serve to eliminate pathogens, dead cells and tissue debris
after various acute assaults, but are also conspicuous in
several neurodegenerative diseases, including AD [15, 35,
46]. An inflammatory stimulus typically induces cytokines
such as IL-1b or TNF-a, which in turn activates a variety of
cells (endothelial cells, microglia/macrophages, astrocytes)
to release cell-attractant chemokines such as CCL2 [6, 23],
and up-regulate expression of cell adhesion molecules such
as ICAM-1 [29].
Previous studies have implicated endothelial HS in
various inflammation models [60]. HS may function as a
ligand for leukocyte L-selectin, as a carrier in chemokine
transcytosis, and as a scaffold for presenting chemokines at
the luminal surface of the endothelium. In the present
work, we have specifically studied the various roles of HS
in neuroinflammation by employing Hpa-tg mice that
overexpress heparanase in multiple regions of the CNS,
thus having HSPGs with truncated HS side chains (Fig. 1).
Two inflammation models were assessed, one involving
systemic LPS challenge, the other a local microinjection of
fibrillar Ab42. Ctr mice subjected to intraperitoneal LPS
injection showed increased levels of cerebral IL-1b
(Fig. 2k) and an abundance of monocytes adhering to and
migrating across the wall of cerebral microvasculature
(Fig. 2a–g), where they differentiated into CD45/ICAM-1
positive macrophages (Fig. 7). Moreover, there was mas-
sive activation of microglia to macrophage-like state as
shown by up-regulated CD45 expression and ramified
Fig. 6 Expression of CCL2 and ICAM-1 at the intracortical Ab42
injection site. a, b Brain sections from a Ctr mouse 4 weeks and a
Hpa-tg mouse 2 weeks after Ab42 injection were immunostained
with anti-CCL2 antibody. The Ctr mouse showed pronounced cell-
associated CCL2 immunosignals close to the injection site (a dis-
persed deposit) compared with scant signals in a Hpa-tg brain section
(b compact deposit). The sites of the initial deposits are identified by
dashed lines; the inserts show residual Ab deposits (green) detected
by the anti-Ab antibody 6E10. The red signal surrounded by the
dashed line in b is not associated with cells and is likely due to
nonspecific fluorescence. c, d Brain tissue sections from a Ctr mouse
as shown in Fig. 3c and a Hpa-tg mouse as shown in Fig. 5d were
immunostained with anti-ICAM-1 antibody. ICAM-1 immunosignals
restricted to the injection site (indicated by asterisk) were pronounced
in Ctr brain (c) but scarce in Hpa-tg brain (d)
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Fig. 7 Expression of ICAM-1 by CD45-positive macrophages in
brains of mice 20 h after intraperitoneal LPS challenge. a–f Paren-
chymal CD45-positive macrophages expressing ICAM-1. Brain tissue
sections of a Ctr and a Hpa-tg mouse challenged by LPS were
immunostained with anti-ICAM-1 (a–b) or double immunostained
with anti-ICAM-1/CD45 antibodies (c–f). a Abundant cell-associated
ICAM-1 immunosignals in the hippocampus of the Ctr mouse (some
of the cells are indicated by arrows), b scant ICAM-1-positive cells in
the hippocampus of the Hpa-tg mouse. Note: Similar nonspecific
background fluorescence from the CA regions and dentate gyrus.
c amoeboid CD45-positive macrophages, d ICAM-1 immunosignals,
e overlay of ICAM-1 immunosignals with CD45-positive macro-
phages. f Enlarged image of a CD45-positive macrophage expressing
ICAM-1 as framed in e. g–n Expression of ICAM-1 in parenchymal
microvasculature. Brain tissue sections of the same animals as above
were double immunostained with anti-CD31/anti-ICAM-1 antibodies.
g, i Microvasculature stained by CD31 in Ctr and Hpa-tg mouse,
respectively. h ICAM-1 immunosignals in Ctr mouse microvascula-
ture. j ICAM-1 immunosignals in Hpa-tg mouse microvasculature
(arrows point ICAM-1 immunosignals). k Abundant ICAM-1-
positive cells associated with a micro-blood vessel in Ctr brain.
m In contrast, a Hpa-tg micro-blood vessel is almost devoid of
ICAM-1-positive cells. l, n Enlarged image of the frame in k and m,
respectively. An arrow in l points to an ICAM-1-positive cell
associated with the parenchymal abluminal surface of the blood
vessel. o–r Expression of ICAM-1 by blood-borne macrophages
associated with microvasculature. o CD45-positive blood-borne
monocytes/macrophages. p ICAM-1 immunosignals. q Overlay of
ICAM-1 immunosignals with CD45-positive monocyte/macrophages.
Arrow indicates expression of ICAM-1 by a CD45-positive cell still
within the blood vessel. r Enlarged image of a CD45 positive
macrophage expressing ICAM-1 as framed in q
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morphology (Fig. 2h–j). All of these effects were signifi-
cantly attenuated in Hpa-tg mice (shown in the
corresponding figures).
The effects of injected fibrillar Ab, as expected, were
essentially confined to brain areas in close vicinity to the
protein deposition. Ctr mice showed massive infiltration of
activated immune cells, including macrophages (presum-
ably derived from both resident microglia and blood-borne
monocytes) and astrocytes (Fig. 4). These CD45-positive
macrophages expressed CCL2 (Supplementary Fig. 4), a
chemoattractant with a central role in the recruitment of
blood-borne monocytes to sites of tissue injury. Expression
of the proteolytic enzymes, NEP and MMP-9 (Fig. 5;
Supplementary Fig. 3), together with phagocytosis of Ab
by macrophages (Fig. 4e–h) presumably contributed to
efficient dispersion of the Ab deposits following intracor-
tical injection (Fig. 4). Again, heparanase expression
strongly attenuated all of these responses to challenge.
A schematic overview of relevant steps of the neuroin-
flammatory process is provided in Fig. 9a, along with the
consequences of heparanase overexpression in Fig. 9b.
Such effects, presumably due to truncation of HS chains,
are discerned at several stages. Interaction of endothelial
HSPGs with L-selectin contributes to the initial stages of
monocyte tethering to the vascular endothelium [60]. HS
chains of sufficient length are required for presentation of
chemokines to monocyte receptors to arrest the cells, and
ensure firm adhesion of the cells to the endothelium
through interaction of ICAM-1 on the endothelium with
ICAM-1 receptors on monocytes, a key step in diapedesis.
Moreover, HSPGs serve as carriers of chemokines in
transcytosis from the parenchymal abluminal to the luminal
aspect of the vascular endothelium [40]. Activation of
resident microglia may be induced by pro-inflammatory
molecules [21]), but also through direct interaction
between Ab and cell-surface HSPG [17]. Notably, LPS-
induced upregulation of TNF-a and IL-1b was inhibited in
Hpa-tg primary microglia compared with Ctr cells (our
unpublished data). The poor response of Hpa-tg mice to
either systemic LPS challenge or local Ab injection, with
scant recruitment of activated macrophages from blood-
borne monocytes and resident microglia is thus due to
failing HSPG support. Our data implicate heparanase as a
potential key modulator of neuroinflammation.
The critical role for endothelial HS in trans-BBB dia-
pedesis, suggested by the attenuating effects of heparanase,
was supported by experiments involving an in vitro model
of monocyte transmigration across a BBB using primary
Fig. 8 Monocyte
transmigration assay using an in
vitro BBB model. a Diagram of
the BBB model assembled in
cell-culture transwell inserts
with primary endothelial cells
(apical site) and pericytes
(basolateral site) isolated from
mouse brains. Heparanase
overexpression in Hpa-tg
endothelial cells (b) and
pericytes (d) compared with Ctr
cells (c, e) was verified by
immunostaining with anti-
heparanase antibody 733
(green). f Gel chromatography
(Superose 12) showed a
pronounced reduction in size of
metabolically 35S-labeled HS
free chains purified from Hpa-tg
primary endothelial cells
compared with HS from Ctr
endothelial cells. g Number of
monocytes transmigrated from
the apical to the basolateral
compartment containing CCL2
(50 ng/ml)
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cerebral vascular cells. Cells derived from Hpa-tg mice
overexpressed heparanase (Fig. 8b–e) and displayed trun-
cated HS chains compared to Ctr cells (Fig. 8f). The
passage of monocytes through the Hpa-tg BBB in response
to CCL2 was significantly reduced relative to the Ctr BBB.
Notably, chemokines, including CCL2, bind to HS as
oligomers [26, 43] that occupy extended domains of the
saccharide chain. For example, a dimer of the chemokine
IL-8 requires a minimal sequence of 18 monosaccharide
units for interaction [53]. The marked susceptibility of
CCL2 function to HS cleavage is thus readily explained.
AD is a chronic disease, with Ab deposition as a hall-
mark in the brain that is not simply modeled by
microinjection of aggregated Ab. Nevertheless, the effects
of cerebral heparanase have potential bearing on various
aspects of the disease. HS binds Ab, supports fibril for-
mation, and is typically part of Ab deposits [39, 59]. Cell-
surface HSPGs have been implicated in Ab uptake and
cytotoxicity [17, 28, 48]. These effects are, by and large,
associated with disease pathogenesis, whereas our present
findings expose HS also as potentially beneficial, contrib-
uting to recruitment and activation of immune cells that
eliminate Ab deposits. The HS/heparanase system is likely
of key importance in the inflammatory response to AD.
Endogenous heparanase is detected in the vasculature of
the AD brain and of the Tg-2576 mouse model of Ab
deposition (Supplementary Fig. 8), thus it is present at the
BBB and potentially capable of interfering with
Fig. 9 Schematic illustration of immune cell recruitment in response
to LPS challenge and to microinjection of aggregated Ab, illustrating
the proposed inhibitory effect of heparanase. a Ctr: 1a–1f transmi-
gration of blood-borne monocytes across the endothelial barrier in
response to systemic LPS challenge. 1a LPS challenge; 1b monocyte
tethering through interactions of cell-surface L-selectin with HS for
cell rolling; 1c monocyte activation by HS-bound chemokine
oligomers (e.g. CCL2) binding to specific receptors (CCR2); 1d
monocyte adhesion to endothelium through interaction of endothelial
ICAM-1 with monocyte ICAM-1 receptors; 1e monocytes upregulate
CD45 and ICAM-1; 1f monocytes transmigrate through the endothe-
lial barrier into the brain, where they differentiate into activated
macrophages and release cytokines (e.g. IL-1b) and chemokines (e.g.
CCL2). 2a–2c Activation of resident microglia in response to Ab
injection: 2a Ab deposit stimulates differentiation of resident
microglia (2b) into activated macrophages; 2c Cytokines released
by the macrophages promote further activation and differentiation of
resident microglia. Similar transition may be elicited by cytokines/
chemokines released due to LPS stimulation. 3a–3b Chemokines bind
to HS chains of HSPGs at the abluminal surface of the endothelium,
and are relayed by transcytosis to the luminal surface where they are
presented to their receptors on tethered monocytes. 4a Activated
macrophages, presumably derived mainly from blood-borne mono-
cytes, disperse the Ab deposits through phagocytosis and proteolytic
degradation. b Hpa-tg: Contrary to Ctr mice, Hpa-tg mice showed
reduced expression of (1b) CD45 and ICAM-1 in response to LPS
challenge (1a), as well as reduced response of resident microglia to
Ab injection (dashed arrows 2a, 2b). 3a–3b Fragmentation of HS
chains in the Hpa-tg brain downregulates binding of chemokines to
HSPGs. These monocytes fail to attach and transmigrate, resulting in
impaired Ab clearance
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transmigration of phagocytes into the injured brain. In AD
and the transgenic mouse models of AD, blood-derived
macrophages associate with Ab deposits [13, 31]. Such
macrophages, recruited in response to cerebral injection of
pre-aggregated Ab, are thought to be better Ab phagocytes
than brain resident immune cells [10, 12, 24, 51], and poor
infiltration of blood-borne macrophages may therefore
contribute to Ab accumulation [57]. Overexpressing hep-
aranase in the brain of an AbPP-transgenic mouse by cross-
breeding with a Hpa-tg mouse may clarify the relative roles
of HS and heparanase in the Ab pathology of AD.
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